Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Targeting the HPGDS-PGD2 axis to treat Th17 cell-mediated autoimmunity in multiple sclerosis

Th17 cells are central drivers of autoimmune pathology, including multiple sclerosis (MS), yet the endogenous metabolic signals that shape their pathogenic differentiation remain incompletely defined. Prostaglandin D₂ (PGD2) is traditionally viewed as an extracellular mediator in allergic diseases. Here, we identify PG...

Yu-Xin Zhuang, Kawai Lei, Yan Li et al. · 0 citations
Jul 2026

ADMET-Driven Chemical Navigability Rules for Early-Stage Virtual Compound Prioritization

Clinical attrition in drug development is frequently driven by suboptimal pharmacokinetic and toxicological (ADMET) properties rather than inadequate target efficacy. Accordingly, early-stage ADMET assessment has become an increasingly important component of Structure-Based Drug Design (SBDD). Here, we present empirica...

J. Encinar, Chen Yang, Raquel Fernández-Ginés et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.